I must admit that fully funding what (at present) amounts pretty much to a research division, makes our bottom line look less attractive than it could be. Pictures of the professor on some ski slope don't do much for me -- but addressing a conference to announce a cure for herpes would. If the company was only focused on further developing the hospital infusion equipment side and fast tracking uses for our world leading ADAPT technology, then I think that our rapid growth would be almost a certainty and I would be assured of finally getting my investment back.
Overall; I feel that retaining the vax side of this company is a bit like gripping a wolf by the ears ....... don't want to hold it but don't dare to let go.
AHZ is 2 companies -why not split into 2?, page-6
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
0.000(0.00%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $13.33 | $13.91 | $13.14 | $302.2K | 22.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 299 | $13.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.49 | 35 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |